Plain-English translation of NCT03036150 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied whether , a daily tablet, could help protect the kidneys and reduce serious heart and kidney-related events in people with chronic kidney disease. Participants were divided into two groups: some received the medication while others received a placebo (a pill with no active ingredient), and researchers compared how their kidney disease progressed over time. The study involved over 4,300 people from multiple countries and was designed to last until enough events occurred to answer the research question.
Chronic kidney disease is a serious condition that often leads to kidney failure, heart disease, and death, even when patients receive standard treatments. Researchers wanted to test whether this medication could offer additional protection beyond the medicines people already take for their kidneys.
Participants were randomly assigned to take either the medication or a matching placebo once daily, in addition to their regular kidney disease treatments. They attended visits where researchers monitored their kidney function through blood and urine tests and tracked whether they experienced any heart or kidney-related events. The study continued until enough clinical events occurred to show whether the medication was effective—a process that took several years.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States